Brexanolone injection may bring relief from postpartum depression within three days, though some questions remain
The first ever medication indicated to treat moderate to severe postpartum depression by helping regulate the hormone levels that drop after childbirth has received FDA approval.
Designated a breakthrough therapy, FDA gave the medication, brexanolone injection, priority review. This is particularly timely as Ob/Gyns implement the new recommendations from the American College of Obstetricians and Gynecologists (ACOG) for earlier, and more frequent, postpartum care.
Read more at ConslultQD…